menu
    • menu
    [{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Neurology","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Advanced Technology International","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Funding","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ Advanced Technology International","highestDevelopmentStatusID":"6","companyTruncated":"Pinteon Therapeutics \/ Advanced Technology International"},{"orgOrder":0,"company":"Pinteon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"PNT001","moa":"Cis-pT231 tau","graph1":"Neurology","graph2":"Preclinical","graph3":"Pinteon Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pinteon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Pinteon Therapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Pinteon Therapeutics

    Menu

    Pinteon Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pinteon Therapeutics Encouraged by Publication of Preclinical Study Supporting PNT001 for the Treatment of Tau...

                            Details : As PNT001 is a humanized version of this antibody, this study provides further evidence for the ability of PNT001 to treat the cognitive impairments seen in tauopathies like Alzheimer’s disease and other neurodegenerative disorders.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 28, 2021

                            Lead Product(s) : PNT001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Advanced Technology International

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Pinteon Therapeutics Announces $3M Award from Advanced Technology International to Support Phase 1 Study of PN...

                            Details : Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope that has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 17, 2021

                            Lead Product(s) : PNT001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Advanced Technology International

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT001

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pinteon Therapeutics Announces Promising Phase 1 Data for Novel Tau Antibody PNT001

                            Details : PNT001 is a monoclonal antibody targeting an epitope on a highly neurotoxic conformation of the tau protein called cis-pT231 tau. According to the data, PNT001 was demonstrated to be well-tolerated in healthy volunteers.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 01, 2021

                            Lead Product(s) : PNT001

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Pinteon Therapeutics

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PNT001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

                            Details : PNT001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Injuries, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : PNT001

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : US Department of Defense

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth